Federation des caisses Desjardins du Quebec’s BioXcel Therapeutics BTAI Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	-$2	–	2900
2025 Q2	$2	Sell	1 -2	-67%	-$3	﹤0.01%	2718
2025 Q1	$6	Sell	3 -4	-57%	-$15	﹤0.01%	2644
2024 Q4	$42	Hold	7	–	–	﹤0.01%	2521
2024 Q3	$69	Hold	7	–	–	﹤0.01%	2504
2024 Q2	$145	Hold	7	–	–	﹤0.01%	2358
2024 Q1	$319	Hold	7	–	–	﹤0.01%	2274
2023 Q4	$333	Hold	7	–	–	﹤0.01%	2229
2023 Q3	$286	Hold	7	–	–	﹤0.01%	2253
2023 Q2	$753	Hold	7	–	–	﹤0.01%	2161
2023 Q1	$2.11K	Hold	7	–	–	﹤0.01%	2074
2022 Q4	$2.43K	Hold	7	–	–	﹤0.01%	2176
2022 Q3	$1.34K	Hold	7	–	–	﹤0.01%	2313
2022 Q2	$1.49K	Hold	7	–	–	﹤0.01%	2349
2022 Q1	$2.36K	Hold	7	–	–	﹤0.01%	2334
2021 Q4	$2.3K	Hold	7	–	–	﹤0.01%	2341
2021 Q3	$3.43K	Buy	7 +4	+133%	+$1.76K	﹤0.01%	2340
2021 Q2	$1.16K	Buy	+3	New	+$1.64K	﹤0.01%	2430

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's BTAI Position: Q3 2025 in Review

Federation des caisses Desjardins du Quebec sold out of BioXcel Therapeutics (BTAI) in Q3 2025, closing a stake of 1 share — an estimated $2 sold.

Federation des caisses Desjardins du Quebec first reported a position in BTAI in Q2 2021 and held it in 17 quarters. The position peaked at $3.43K in Q3 2021. 35 funds tracked by Wall St. Rank hold BTAI as of Q3 2025.

Federation des caisses Desjardins du Quebec reported no remaining BioXcel Therapeutics position as of Q3 2025 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 1 BioXcel Therapeutics share in Q3 2025, an estimated $2.
Federation des caisses Desjardins du Quebec first reported a position in BioXcel Therapeutics in Q2 2021 and held it in 17 quarters.
Federation des caisses Desjardins du Quebec's BioXcel Therapeutics position peaked at $3.43K in Q3 2021.
35 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2025.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q3 2025, filed 14 Nov 2025.